Literature DB >> 21739190

Acceleration of in vitro dissolution studies of sustained release dosage form of theophylline and in vitro-in vivo evaluations in terms of correlations.

Gökhan Ertan1, Ercüment Karasulu, Işık Ozgüney, Yeşim Karasulu, Sebnem Apaydın, Gülten Kantarcı, Aysu Yurdasiper, Mehmet Ali Ege.   

Abstract

The aim of the study was to accelerate the dissolution of the sustained release dosage forms using both elevated temperature and high rpm rates. Teokap(®) SR 200 mg pellets were tested by in vitro sustained and accelerated dissolution studies using USP XXIII rotating paddle method. Sustained dissolution studies were carried out for 12 h in phosphate buffer at 37 ± 0.5°C and 50 rpm. Accelerated dissolution studies were performed for 48 min in distilled water at 90 ± 1°C and 250 rpm. The results obtained from accelerated and sustained dissolution studies were correlated using both linear and linear kinetic correlation methods by a computer program. While r (2) and maximum error between calculated and observed drug release rates were found to be 0.9129 and 15.9%, respectively, in linear correlation method, these values were observed as 0.9938 and 3.6%, respectively, in linear kinetic correlation method. In vivo plasma concentration data were obtained from six New Zealand rabbits after administration of a single dose of Teokap(®) SR 200 mg pellet. Then, the results of in vivo study were evaluated with in vitro accelerated and sustained dissolution results by applying them to in vitro-in vivo linear correlations. As a result of these correlations, it was shown that the in vitro correlation plots were very similar to the plot which was obtained by the in vivo study (f (2) = 73.81-77.11). This study suggested a way to prevent the loss of time for routine dissolution studies of sustained release preparations for quality control procedures using in vitro accelerated dissolution tests. The storage and quarantine periods of the product in process and process controls in the manufactories could be shortened by this method. Calculation of the in vivo performance of sustained release dosage forms using the results of the accelerated dissolution studies may be counted as another advantage of the method.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739190     DOI: 10.1007/s13318-011-0049-6

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  19 in total

1.  Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

Authors:  Andreas Billich; Heinrich Aschauer; András Aszódi; Anton Stuetz
Journal:  Int J Pharm       Date:  2004-01-09       Impact factor: 5.875

2.  Simulation of drug release from biodegradable polymeric microspheres with bulk and surface erosions.

Authors:  Mingping Zhang; Zichao Yang; Li-Ling Chow; Chi-Hwa Wang
Journal:  J Pharm Sci       Date:  2003-10       Impact factor: 3.534

3.  Accelerated dissolution rate analysis (ACDRA) for controlled release drugs. Application to Roxiam.

Authors:  G Zackrisson; G Ostling; B Skagerberg; T Anfält
Journal:  J Pharm Biomed Anal       Date:  1995-04       Impact factor: 3.935

4.  A short term (accelerated release) approach to evaluate peptide release from PLGA depot-formulations.

Authors:  M Shameem; H Lee; P P DeLuca
Journal:  AAPS PharmSci       Date:  1999

5.  Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.

Authors:  Ana R Breier; Clésio S Paim; Martin Steppe; Elfrides E S Schapoval
Journal:  J Pharm Pharm Sci       Date:  2005-08-11       Impact factor: 2.327

6.  Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion?

Authors:  C Witt; T Kissel
Journal:  Eur J Pharm Biopharm       Date:  2001-05       Impact factor: 5.571

7.  Kinetics of absorption of a new once-a-day formulation of theophylline in the presence and absence of food.

Authors:  L I Harrison; A K Mitra; C R Kehe; N M Klinger; K A Wick; S E McCarville; K M Cooper; S F Chang; P J Roddy; S M Berge
Journal:  J Pharm Sci       Date:  1993-06       Impact factor: 3.534

8.  Evaluation of an acetic acid ester of monoglyceride as a suppository base with unique properties.

Authors:  A K Dash; G C Cudworth
Journal:  AAPS PharmSciTech       Date:  2001-07-17       Impact factor: 3.246

9.  Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.

Authors:  Yihong Qiu; J Garren; E Samara; G Cao; C Abraham; H S Cheskin; K R Engh
Journal:  J Pharm Sci       Date:  2003-11       Impact factor: 3.534

10.  Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.

Authors:  E B Souto; S A Wissing; C M Barbosa; R H Müller
Journal:  Int J Pharm       Date:  2004-06-18       Impact factor: 5.875

View more
  1 in total

1.  A short term quality control tool for biodegradable microspheres.

Authors:  Susan D'Souza; Jabar A Faraj; Rossella Dorati; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2014-02-12       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.